RAPP — Rapport Therapeutics, Inc. Common Stock stock price, charts and financials
QT73Rapport Therapeutics, Inc. Common StockRapport Therapeutics, Inc. Common Stock (NASDAQ: RAPP) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 31.44% | Shs Outstand | 47.83M | Perf Week | -7.27% |
| Market Cap | 1.93B | Forward P/E | - | EPS next Y | -4.97 | Insider Trans | -7.14% | Shs Float | 22.88M | Perf Month | -17.57% |
| Enterprise Value | 1.88B | PEG | 0.62 | EPS next Q | -1.21 | Inst Own | - | Short Float | 4.67% | Perf Quarter | 8.33% |
| Income | -138.13M | P/S | 96.73 | EPS this Y | - | Inst Trans | - | Short Ratio | 6.31 | Perf Half Y | 47.31% |
| Sales | 20.00M | P/B | 4.54 | EPS next Y | -23.23% | ROA | -29.88% | Short Interest | 2.23M | Perf YTD | 33.32% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -29.02% | 52W High | 52.93 -23.58% | Perf Year | 53.80% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -35.45% | 52W Low | 23.75 70.32% | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | - | Volatility | 4.88% 4.44% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 94.05 | EPS Y/Y TTM | 19.58% | Oper. Margin | -767.58% | ATR (14) | 2.14 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 15.72 | Sales Y/Y TTM | - | Profit Margin | -685.80% | RSI (14) | 32.38 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 15.72 | EPS Q/Q | -58.67% | SMA20 | -12.80% | Beta | 1.26 | Target Price | 64.80 |
| Payout | 0.00% | Debt/Eq | 0.02 | Sales Q/Q | - | SMA50 | -9.67% | Rel Volume | 2.75 | Prev Close | 41.95 |
| Employees | 84 | LT Debt/Eq | 0.02 | Earnings | Nov 05 | SMA200 | 13.97% | Avg Volume | 363.38K | Price | 40.45 |
| IPO Date | Jun 07, 2024 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -6.29% 166.67% | Net Debt/EBITDA | 0.36 | Volume | 998,056 | Change | -3.58% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-16-26 | Reiterated | BTIG | Buy | $65 → $75 |
| Aug-17-26 | Reiterated | Raymond James | $66 → $75 | |
| Aug-12-26 | Reiterated | HC Wainwright & Co. | Buy | $40 → $66 |
| Jun-24-26 | Initiated | Leerink | Outperform | $52 |
| May-21-26 | Reiterated | BTIG | Buy | $47 → $65 |
| May-18-26 | Reiterated | Truist Financial | $44 → $56 | |
| Apr-10-26 | Initiated | Raymond James | Strong Buy | $66 |
| Feb-02-26 | Initiated | Wells Fargo | Overweight | $51 → $43 |
| Dec-19-25 | Reiterated | Wells Fargo | $51 | |
| Dec-09-25 | Reiterated | HC Wainwright & Co. | Buy | $40 |
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | |
|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | — | |
| Gross Profit | 0 | 0 | 0 | — | |
| Selling, General and Administrative Excl. Other | 30 | 22 | 8 | — | |
| Research and Development | 95 | 61 | 28 | — | |
| Other Operating Expense | 0 | 0 | 0 | — | |
| Operating Income | -125 | -83 | -36 | — | |
| Interest Expense | 0 | 0 | 0 | — | |
| Unusual Expense | — | — | — | — | |
| Non-Operating Income (Expense) | 14 | 5 | 1 | — | |
| Net Income Before Taxes | -111 | -78 | -35 | — | |
| Income Taxes | 0 | 0 | 0 | — | |
| Consolidated Net Income | -111 | -78 | -35 | — | |
| Net Income From Continuing Operations | -111 | -78 | -35 | — | |
| Net Income | -111 | -78 | -35 | — | |
| EPS (Recurring) | -2.86 | -3.78 | -0.95 | — | |
| EPS (Basic, Before Extraordinaries) | -2.86 | -3.78 | -0.95 | — | |
| EPS (Diluted) | -2.86 | -3.78 | -0.95 | — | |
| EBITDA | -124 | -82 | -36 | — | |
| Other After Tax Adjustments | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | |
| Gross Margin | — | — | — | — | |
| Operating Margin | — | — | — | — | |
| Net Margin | — | — | — | — | |
| Shares Outstanding | 47 | 21 | 18 | — | |
| Market Capitalization | 1,426 | 373 | — | — | |
| Operating Lease Expense | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Ceesay Abraham | Chief Executive Officer | Sep 08 '26 | Sale | 45.61 | 8,210 | 374,498 | 458,977 | Sep 09 |
| Yeleswaram Krishnaswamy | Chief Development Officer | Aug 25 '26 | Sale | 50.64 | 37,000 | 1,873,605 | 195,862 | Aug 26 |
| Ceesay Abraham | Chief Executive Officer | Aug 25 '26 | Sale | 49.57 | 18,921 | 937,957 | 467,187 | Aug 26 |
| Yeleswaram Krishnaswamy | Chief Development Officer | Aug 24 '26 | Sale | 50.00 | 13,160 | 657,978 | 232,862 | Aug 26 |
| Yeleswaram Krishnaswamy | Chief Development Officer | Aug 19 '26 | Sale | 49.90 | 404 | 20,160 | 246,022 | Aug 20 |
| Ceesay Abraham | Chief Executive Officer | Aug 11 '26 | Sale | 48.01 | 28,958 | 1,390,404 | 486,108 | Aug 12 |
| Ceesay Abraham | Chief Executive Officer | Aug 10 '26 | Sale | 46.26 | 22,541 | 1,042,772 | 515,066 | Aug 12 |
| Ceesay Abraham | Chief Executive Officer | Jul 27 '26 | Sale | 42.11 | 2,210 | 93,061 | 537,607 | Jul 29 |
| Ceesay Abraham | Chief Executive Officer | Jul 14 '26 | Sale | 40.00 | 8,210 | 328,437 | 539,817 | Jul 15 |
| Gault Cheryl | Chief Operating Officer | Jun 30 '26 | Sale | 41.58 | 10,000 | 415,799 | 149,914 | Jul 01 |
| Ceesay Abraham | Chief Executive Officer | Jun 29 '26 | Sale | 39.83 | 8,220 | 327,398 | 548,027 | Jul 01 |
| Third Rock Ventures V, L.P. | 10% Owner | May 26 '26 | Sale | 40.05 | 18,572 | 743,753 | 6,280,525 | May 28 |
| Third Rock Ventures V, L.P. | 10% Owner | May 11 '26 | Sale | 40.24 | 133,618 | 5,377,323 | 6,299,097 | May 13 |
| Third Rock Ventures V, L.P. | 10% Owner | May 08 '26 | Sale | 40.31 | 5,018 | 202,256 | 6,432,715 | May 11 |
| Third Rock Ventures V, L.P. | 10% Owner | May 07 '26 | Sale | 40.12 | 271,495 | 10,892,651 | 6,437,733 | May 11 |